DBVT

DBV Technologies S.A.

Price Chart

Latest Quote

$15.53

-0.75 (-4.61%)

Current Price

Previous Close	$16.28
Open	$16.64
Day High	$16.69
Day Low	$15.43
Volume	319,143

Fetched: 2026-06-19T18:33:10

Stock Information

Shares Outstanding	59.19M
Total Debt	$6.10M
Cash Equivalents	$229.20M
Revenue	$5.74M
Net Income	$-167.45M
Sector	Healthcare
Industry	Biotechnology
Market Cap	$919.17M
EPS (TTM)	$-4.53
Exchange	NCM

🌐 Visit Website

📊 Comprehensive Analysis

Company Data

Enterprise Value	$696.01M
Sales	$5.74M
Income	$-167.45M
Book/sh	$3.52
Cash/sh	$3.87
Employees	161

Financial Ratios

Quick Ratio	4.72
Current Ratio	4.76
Debt/Eq	2.93

Returns & Margins

ROA	-66.36%
ROE	-158.89%
Gross Margin	100.00%
Operating Margin	-5311.11%

Ownership

Institutional Ownership	37.23%
Insider & Institutional transactions data not available

Valuation Ratios

Forward P/E	-31.99
P/S	160.25
P/B	4.42

Analyst Data

Recommendation	buy
Target Price	$40.11

Technical Indicators

SMA20	$17.46
SMA50	$19.08
SMA200	$17.61
RSI	27.14
ATR	1.0714

Shares Float	35.25M
Short Float	2.82%
Short Ratio	7.31
Volatility	-0.22
Rel Volume	1.10

Performance History

Week	-6.11%
Month	-16.10%
Quarter	-20.15%
6 Months	-13.63%
YTD	-18.48%
Year	+63.99%
3 Years	+304.43%
5 Years	+27.09%
10 Years	-74.67%

Stock Score: ⭐ Premium

Based on debt, profitability, growth, and cash flow metrics

⭐ Premium Feature

Recent Price History

Date	Close	Volume
2026-06-18	$15.53	320,300
2026-06-17	$16.28	225,100
2026-06-16	$16.75	160,800
2026-06-15	$18.12	175,900
2026-06-12	$17.42	991,700
2026-06-11	$16.54	92,200
2026-06-10	$16.04	297,800
2026-06-09	$16.03	117,900
2026-06-08	$16.00	178,500
2026-06-05	$16.59	273,500
2026-06-04	$17.58	173,300
2026-06-03	$17.70	162,600
2026-06-02	$18.23	251,700
2026-06-01	$18.80	180,900
2026-05-29	$19.10	270,300
2026-05-28	$18.99	420,300
2026-05-27	$18.50	1,070,000
2026-05-26	$18.16	175,200
2026-05-22	$18.18	93,000
2026-05-21	$18.57	168,100
2026-05-20	$18.54	108,200
2026-05-19	$18.51	118,100

About DBV Technologies S.A.

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products in France. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis. The company's earlier stage research programs include celiac disease. In addition, the company develops Viaskin technology platform, a platform to potentially treat food allergy. It has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Châtillon, France.

📰 Latest News

DBV Technologies (ENXTPA:DBV) Advances Peanut Patch With New Phase 3 Data And Infant Trial

Simply Wall St. • 2026-06-17T20:15:40Z

European Equities Traded in the US as American Depositary Receipts Slightly Higher in Tuesday Trading

MT Newswires • 2026-06-16T15:08:44Z

DBV Technologies (DBVT) Soars 5.3%: Is Further Upside Left in the Stock?

Zacks • 2026-06-15T11:59:00Z

European Equities Traded in the US as American Depositary Receipts Increase in Friday Trading; Rise for Week

MT Newswires • 2026-06-12T15:14:33Z

European Equities Traded in the US as American Depositary Receipts Decline in Friday Trading; Rise for Week

MT Newswires • 2026-06-05T15:06:40Z

European Equities Traded in the US as American Depositary Receipts Rise in Thursday Trading

MT Newswires • 2026-06-04T15:08:32Z

European Equities Traded in the US as American Depositary Receipts Rise in Tuesday Trading

MT Newswires • 2026-06-02T15:08:08Z

European Equities Traded in the US as American Depositary Receipts Little Changed in Thursday Trading

MT Newswires • 2026-05-21T15:05:36Z

European Equities Traded in the US as American Depositary Receipts Open Week Tracking Higher in Monday Trading

MT Newswires • 2026-05-18T15:11:28Z

European Equities Traded in the US as American Depositary Receipts Flat in Wednesday Trading

MT Newswires • 2026-05-13T15:12:40Z

Period:

Income Statement (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Revenue
Total Revenue	$0	$0	$0	$0
Operating Revenue	$0	$0	$0	$0
Expenses
Total Expenses	$147,054,000	$116,590,000	$76,433,000	$96,631,000
Net Non Operating Interest Income Expense	$601,000	$2,726,000	$3,714,000	$427,000
Total Other Finance Cost	$-601,000	$-2,726,000	$-3,714,000	$-427,000
Operating Expense	$147,054,000	$116,590,000	$76,433,000	$96,631,000
General And Administrative Expense	$28,277,000	$23,854,000	$22,777,000	$17,563,000
Other Operating Expenses	-	$-5,000	$-6,962,000	$874,000
Other Income Expense	-	-	-	-
Selling And Marketing Expense	-	-	-	-
Income & Earnings
Net Income From Continuing Operation Net Minority Interest	$-146,947,000	$-113,918,000	$-72,726,000	$-96,274,000
Net Interest Income	$601,000	$2,726,000	$3,714,000	$427,000
Normalized Income	$-146,947,000	$-113,918,000	$-72,726,000	$-96,274,000
Net Income From Continuing And Discontinued Operation	$-146,947,000	$-113,918,000	$-72,726,000	$-96,274,000
Total Operating Income As Reported	$-147,056,000	$-116,589,000	$-76,432,000	$-96,631,000
Net Income Common Stockholders	$-146,947,000	$-113,918,000	$-72,726,000	$-96,274,000
Net Income	$-146,947,000	$-113,918,000	$-72,726,000	$-96,274,000
Net Income Including Noncontrolling Interests	$-146,947,000	$-113,918,000	$-72,726,000	$-96,274,000
Net Income Continuous Operations	$-146,947,000	$-113,918,000	$-72,726,000	$-96,274,000
Pretax Income	$-146,456,000	$-113,863,000	$-72,719,000	$-96,204,000
Operating Income	$-147,054,000	$-116,590,000	$-76,433,000	$-96,631,000
Depreciation Amortization Depletion Income Statement	$7,731,000	$7,545,000	$9,161,000	$8,369,000
Depreciation And Amortization In Income Statement	$7,731,000	$7,545,000	$9,161,000	$8,369,000
Special Income Charges	-	-	-	$0
Per Share
Diluted EPS	$-5.25	$-5.85	$-3.80	$-6.20
Basic EPS	$-5.25	$-5.85	$-3.80	$-6.20
Other
Tax Effect Of Unusual Items	$0	$0	$0	$0
Tax Rate For Calcs	$0	$0	$0	$0
Normalized EBITDA (Bullshit earnings)	$-139,323,000	$-109,045,000	$-67,272,000	$-83,469,000
Reconciled Depreciation	$3,194,000	$-925,000	$-13,998,000	$13,162,000
EBITDA (Bullshit earnings)	$-139,323,000	$-109,045,000	$-67,272,000	$-83,469,000
EBIT	$-147,054,000	$-116,590,000	$-76,433,000	$-96,631,000
Diluted Average Shares	$27,914,852	$19,470,085	$19,024,278	$15,532,258
Basic Average Shares	$27,914,852	$19,470,085	$19,024,278	$15,532,258
Diluted NI Availto Com Stockholders	$-146,947,000	$-113,918,000	$-72,726,000	$-96,274,000
Tax Provision	$491,000	$55,000	$7,000	$70,000
Other Taxes	$-5,636,000	$-4,146,000	$-8,766,000	$-5,718,000
Research And Development	$116,682,000	$89,342,000	$60,223,000	$75,543,000
Selling General And Administration	$28,277,000	$23,854,000	$22,777,000	$17,563,000
Other Gand A	$11,039,000	$11,822,000	$10,434,000	$6,641,000
Salaries And Wages	$17,238,000	$12,032,000	$12,343,000	$10,922,000
Total Unusual Items	-	-	-	$0
Total Unusual Items Excluding Goodwill	-	-	-	$0
Restructuring And Mergern Acquisition	-	-	-	$0

Fetched: 2026-06-17

Balance Sheet (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Assets
Net Tangible Assets	$168,748,000	$27,348,000	$140,128,000	$194,444,000
Total Assets	$233,718,000	$65,658,000	$182,986,000	$246,518,000
Total Non Current Assets	$20,775,000	$21,271,000	$24,071,000	$23,444,000
Other Non Current Assets	$-1,000	$-1,000	$6,085,000	$3,740,000
Non Current Accounts Receivable	$620,000	$111,000	-	$312,000
Investmentin Financial Assets	$5,189,000	$4,312,000	-	$1,773,000
Goodwill And Other Intangible Assets	$22,000	$40,000	$58,000	$10,000
Current Assets	$212,943,000	$44,388,000	$158,915,000	$223,074,000
Prepaid Assets	$2,628,000	$1,541,000	$2,103,000	$2,680,000
Receivables	$16,148,000	$10,391,000	$15,446,000	$11,199,000
Other Receivables	$1,577,000	$1,959,000	$1,353,000	$1,504,000
Taxes Receivable	$14,571,000	$8,432,000	$14,093,000	$9,695,000
Cash Cash Equivalents And Short Term Investments	$194,167,000	$32,456,000	$141,367,000	$209,194,000
Cash And Cash Equivalents	$194,167,000	$32,456,000	$141,367,000	$209,194,000
Cash Equivalents	$67,050,000	$0	$130,836,000	$179,090,000
Cash Financial	$127,118,000	$32,456,000	$10,530,000	$30,104,000
Other Current Assets	-	-	$-1,000	$1,000
Accounts Receivable	-	-	$0	$0
Non Current Prepaid Assets	-	-	-	$1,773,000
Debt
Total Debt	$7,994,000	$7,797,000	$6,553,000	$4,152,000
Long Term Debt And Capital Lease Obligation	$5,409,000	$6,297,000	$4,526,000	$1,127,000
Current Debt And Capital Lease Obligation	$2,585,000	$1,500,000	$2,027,000	$3,025,000
Current Debt	$1,468,000	$846,000	$883,000	$1,131,000
Other Current Borrowings	$1,468,000	$846,000	$883,000	$1,131,000
Liabilities
Total Liabilities Net Minority Interest	$64,948,000	$38,271,000	$42,799,000	$52,065,000
Total Non Current Liabilities Net Minority Interest	$6,923,000	$7,135,000	$5,460,000	$22,544,000
Other Non Current Liabilities	$1,514,000	$838,000	$934,000	$21,417,000
Current Liabilities	$58,025,000	$31,136,000	$37,339,000	$29,521,000
Other Current Liabilities	$13,907,000	$7,416,000	$11,787,000	$9,817,000
Payables And Accrued Expenses	$41,533,000	$22,220,000	$23,525,000	$14,542,000
Payables	$41,533,000	$22,220,000	$23,525,000	$14,542,000
Total Tax Payable	$592,000	$188,000	$223,000	$69,000
Accounts Payable	$40,941,000	$22,032,000	$23,302,000	$14,473,000
Current Deferred Liabilities	-	-	$0	$2,137,000
Equity
Common Stock Equity	$168,770,000	$27,388,000	$140,186,000	$194,454,000
Total Equity Gross Minority Interest	$168,770,000	$27,387,000	$140,187,000	$194,453,000
Stockholders Equity	$168,770,000	$27,388,000	$140,186,000	$194,454,000
Gains Losses Not Affecting Retained Earnings	$-5,430,000	$-12,192,000	$-8,129,000	$-13,800,000
Other Equity Adjustments	$497,000	$905,000	$742,000	$781,000
Retained Earnings	$-393,129,000	$-286,375,000	$-238,862,000	$-259,578,000
Other
Treasury Shares Number	$74,680	$266,868	$222,988	$149,793
Ordinary Shares Number	$235,596,184	$102,580,633	$96,208,782	$93,987,352
Share Issued	$235,670,864	$102,847,501	$96,431,770	$94,137,145
Tangible Book Value	$168,748,000	$27,348,000	$140,128,000	$194,444,000
Invested Capital	$170,238,000	$28,234,000	$141,069,000	$195,585,000
Working Capital	$154,918,000	$13,252,000	$121,576,000	$193,553,000
Capital Lease Obligations	$6,526,000	$6,951,000	$5,670,000	$3,021,000
Total Capitalization	$168,770,000	$27,388,000	$140,186,000	$194,454,000
Foreign Currency Translation Adjustments	$-5,927,000	$-13,097,000	$-8,871,000	$-14,581,000
Treasury Stock	$834,000	$1,309,000	$1,263,000	$1,109,000
Additional Paid In Capital	$541,251,000	$315,613,000	$377,468,000	$458,221,000
Capital Stock	$26,912,000	$11,651,000	$10,972,000	$10,720,000
Common Stock	$26,912,000	$11,651,000	$10,972,000	$10,720,000
Long Term Capital Lease Obligation	$5,409,000	$6,297,000	$4,526,000	$1,127,000
Current Capital Lease Obligation	$1,117,000	$654,000	$1,144,000	$1,894,000
Investments And Advances	$5,189,000	$4,312,000	-	$1,773,000
Available For Sale Securities	$5,189,000	$4,312,000	-	$1,773,000
Net PPE	$14,945,000	$16,809,000	$17,928,000	$17,609,000
Accumulated Depreciation	$-22,876,000	$-17,528,000	$-18,954,000	$-14,788,000
Gross PPE	$37,821,000	$34,337,000	$36,882,000	$32,397,000
Construction In Progress	$1,156,000	$1,185,000	$1,462,000	$4,468,000
Other Properties	$33,137,000	$30,050,000	$30,890,000	$22,972,000
Machinery Furniture Equipment	$3,528,000	$3,102,000	$4,530,000	$1,743,000
Current Deferred Revenue	-	-	$0	$2,137,000
Buildings And Improvements	-	-	$3,327,000	$3,214,000
Properties	-	-	$0	$0

Fetched: 2026-06-17

Cash Flow Statement (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Free Cash Flow
Free Cash Flow	$-121,719,000	$-106,815,000	$-80,330,000	$-56,420,000
Operating Activities
Operating Cash Flow	$-121,181,000	$-104,474,000	$-79,653,000	$-55,666,000
Cash Flow From Continuing Operating Activities	$-121,183,000	$-104,474,000	$-79,653,000	$-55,668,000
Operating Gains Losses	-	-	$76,000	$105,000
Investing Activities
Capital Expenditure	$-538,000	$-2,341,000	$-677,000	$-754,000
Investing Cash Flow	$-1,369,000	$-757,000	$-808,000	$-100,000
Cash Flow From Continuing Investing Activities	$-1,369,000	$-757,000	$-808,000	$-99,000
Net Other Investing Changes	$-831,000	$1,584,000	$-131,000	$-1,000
Financing Activities
Issuance Of Capital Stock	$276,182,000	$634,000	$6,921,000	$194,594,000
Financing Cash Flow	$276,182,000	$587,000	$6,767,000	$194,120,000
Cash Flow From Continuing Financing Activities	$276,182,000	$587,000	$6,767,000	$194,120,000
Net Common Stock Issuance	$276,182,000	$587,000	$6,767,000	$194,594,000
Common Stock Issuance	$276,182,000	$634,000	$6,921,000	$194,594,000
Repurchase Of Capital Stock	-	$-47,000	$-154,000	-
Net Other Financing Charges	-	-	-	$-474,000
Other
End Cash Position	$194,167,000	$32,456,000	$141,367,000	$209,194,000
Beginning Cash Position	$32,456,000	$141,367,000	$209,194,000	$77,301,000
Effect Of Exchange Rate Changes	$8,080,000	$-4,268,000	$5,867,000	$-6,461,000
Changes In Cash	$153,631,000	$-104,643,000	$-73,694,000	$138,354,000
Net Intangibles Purchase And Sale	$-6,000	$-3,000	$0	$0
Purchase Of Intangibles	$-6,000	$-3,000	$0	$0
Net PPE Purchase And Sale	$-532,000	$-2,338,000	$-677,000	$-746,000
Purchase Of PPE	$-532,000	$-2,338,000	$-677,000	$-754,000
Change In Working Capital	$1,340,000	$4,364,000	$953,000	$22,320,000
Change In Other Working Capital	$-203,000	$485,000	$1,662,000	$-2,249,000
Change In Other Current Liabilities	$6,521,000	$366,000	$-5,334,000	$152,000
Change In Other Current Assets	$-4,699,000	$4,629,000	$-3,795,000	$20,961,000
Change In Payables And Accrued Expense	$15,783,000	$272,000	$8,420,000	$3,456,000
Change In Payable	$15,783,000	$272,000	$8,420,000	$3,456,000
Change In Account Payable	$15,783,000	$272,000	$8,420,000	$3,456,000
Change In Inventory	$-16,062,000	$-1,388,000	$0	$0
Other Non Cash Items	$-217,000	$-3,000	$23,000	$-5,000
Stock Based Compensation	$5,387,000	$4,620,000	$6,019,000	$5,026,000
Asset Impairment Charge	$16,062,000	$1,388,000	-	-
Depreciation Amortization Depletion	$3,194,000	$-925,000	$-13,998,000	$13,162,000
Depreciation And Amortization	$3,194,000	$-925,000	$-13,998,000	$13,162,000
Depreciation	$3,194,000	$-925,000	$-13,998,000	$13,162,000
Net Income From Continuing Operations	$-146,947,000	$-113,918,000	$-72,726,000	$-96,274,000
Common Stock Payments	-	$-47,000	$-154,000	-
Pension And Employee Benefit Expense	-	$0	$76,000	$105,000
Net Investment Purchase And Sale	-	-	$-131,000	$647,000
Sale Of Investment	-	-	$154,000	$770,000
Purchase Of Investment	-	-	$-285,000	$-123,000
Sale Of PPE	-	-	$0	$8,000
Change In Receivables	-	-	$0	$0
Changes In Account Receivables	-	-	$0	$0

Fetched: 2026-06-17